XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

Market Reaction – XTLB

-8.22% $0.70

15m delay 2 alerts

-8.22% Since News

$0.70 Last Price

$0.70 $0.77 Day Range

-$646K Valuation Impact

$7M Market Cap

0.0x Rel. Volume

Following this news, XTLB has declined 8.22%, reflecting a notable negative market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.70. This price movement has removed approximately $646K from the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Equity requirement: $2,500,000 Minimum bid price: $1.00 Hearing request deadline: March 4, 2026 +5 more

8 metrics

Equity requirement $2,500,000 Nasdaq stockholders’ equity continued listing standard

Minimum bid price $1.00 Nasdaq Bid Price Rule continued listing standard

Hearing request deadline March 4, 2026 Last date to request Nasdaq hearing to stay delisting

Trading suspension date March 6, 2026 Scheduled Nasdaq suspension if no hearing requested

Shell determination date February 25, 2026 Date of Nasdaq staff delist determination letter

Subsidiary liquidation date February 22, 2026 Court order to liquidate The Social Proxy

Equity notice date January 20, 2026 Nasdaq notice of minimum stockholders’ equity deficiency

Bid price notice date December 20, 2025 Nasdaq notice of minimum $1 bid price deficiency

Market Reality Check

Price: $0.7628 Vol: Volume 9,775 is well belo...

low vol

$0.7628 Last Close

Volume Volume 9,775 is well below the 20-day average of 73,414, indicating limited pre‑news trading interest. low

Technical Shares at 0.7628 are trading below the 200-day MA of 1.13 and about 70% under the 52-week high.

Peers on Argus

XTLB was down 4.61% while biotech peers showed mixed moves (e.g., IMRN -5.1%, AP...

1 Down

XTLB was down 4.61% while biotech peers showed mixed moves (e.g., IMRN -5.1%, APLM -3.72%, PHIO +7.55%, LPTX +238.84%), and only one peer appeared in the momentum scanner, suggesting a stock‑specific reaction.

Historical Context

4 past events · Latest: Jan 29 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Financing/compliance plan	Positive	+1.7%	Update on NeuroNOS deal and up to US$2.0M private placement to address equity.
Jan 23	Equity deficiency notice	Negative	-10.1%	Nasdaq notice of stockholders’ equity deficit versus $2,500,000 listing requirement.
Jan 13	NeuroNOS acquisition	Positive	+56.7%	Agreement to acquire 85% of NeuroNOS with cash, shares, and milestones.
Dec 24	Bid price deficiency	Negative	-5.7%	Nasdaq notice that 30‑day bid fell below $1.00 minimum under Rule 5550(a)(2).

Pattern Detected

Recent Nasdaq‑related notices and capital plans have typically led to price moves that align with the tone of the news, with sharper declines on clearly negative compliance updates.

Recent Company History

Over the past few months, XTLB has been dominated by listing‑compliance and restructuring headlines. A Dec 24, 2025 notice on minimum bid price and a Jan 23, 2026 equity‑deficiency notice both saw negative price reactions. In contrast, the Jan 13, 2026 NeuroNOS acquisition announcement produced a strong positive move of 56.66%. A Jan 29, 2026 update on efforts to close that deal and raise up to US$2.0 million had a modestly positive reaction. Today’s staff delisting determination extends this ongoing Nasdaq risk theme.

Market Pulse Summary

The stock is down -8.2% following this news. A negative reaction despite prior awareness of Nasdaq d...

Analysis

The stock is down -8.2% following this news. A negative reaction despite prior awareness of Nasdaq deficiencies fits the pattern of XTLB selling off on adverse compliance updates. The staff’s shell determination, alongside equity and bid‑price shortfalls, added another potential delisting trigger. Historical news shows sensitivity to such regulatory letters, and uncertainty around the hearing outcome and future operating business can weigh on sentiment. Without clear progress on transactions or a defined operating plan, downside moves have previously been hard to reverse.

Key Terms

american depositary shares, form 25-nse, insolvency proceedings

3 terms

american depositary shares financial

"continued listing of the Company’s American Depositary Shares (“ADSs”) is no longer warranted"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

form 25-nse regulatory

"removed from listing and registration when Nasdaq files a Form 25-NSE with the SEC"

Form 25‑NSE is an official filing used to notify the stock exchange that a company’s securities are being removed from trading on that exchange, similar to handing in a key when a shop closes. Investors care because removal ends public trading on that venue, often cutting liquidity and making it harder to buy or sell shares, which can affect a stock’s price and how quickly investors can access cash or exit positions.

insolvency proceedings regulatory

"filed a formal application ... for the commencement of insolvency proceedings"

A formal legal process used when a company cannot pay its debts, where a court oversees how the company’s assets and obligations are handled — either by reorganizing the business to keep it operating or by selling assets to pay creditors. For investors this matters because it determines who gets paid first and how much, often reducing or wiping out shareholders’ value while giving higher priority to lenders, and it sets the timeline and likelihood of any recovery.

AI-generated analysis. Not financial advice.

RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff’s belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company’s American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel’s decision.

The Letter stated that the Staff believes the Company no longer has an operating business, citing the Company’s prior public disclosure that its wholly owned subsidiary, The Social Proxy, had filed a formal application with the competent Israeli court for the commencement of insolvency proceedings and that on February 22, 2026, the court ordered The Social Proxy's liquidation and the appointment of a trustee for the insolvency proceedings. The Staff noted that the Company’s purported shell status could lead to the ADSs being subject to market abuses and other violative conduct and that purchasers of the Company’s securities do not know what the operating business of the Company will be in the future.

Additionally, and as previously disclosed by the Company, on January 20, 2026 the Staff notified the Company that it did not comply with the minimum $2,500,000 stockholders’ equity requirement and on December 20, 2025, the Staff notified the Company that its ADSs were no longer in compliance with the minimum $1 bid price (the “Bid Price Rule”). In the Letter, the Staff stated that these matters serve as additional and separate bases for delisting the ADSs from Nasdaq, notwithstanding that the Company is currently under a compliance period for the Bid Price Rule.

Unless the Company requests the Hearing by March 4, 2026, trading of the Company’s ADSs will be suspended from The Nasdaq Capital Market at the opening of business on March 6, 2026, and will subsequently be removed from listing and registration when Nasdaq files a Form 25-NSE with the SEC. A timely Hearing request will stay the suspension of the ADSs and delisting pending the Panel’s decision. There can be no assurance that the Panel will grant the Company’s request for continued listing. 

About XTL Biopharmaceuticals Ltd.

XTL is an IP Portfolio company that holds 100% of The Social Proxy Ltd. and IP portfolio including hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) that the company sublicensed. The company actively pursues strategic collaborations and acquisitions to expand its therapeutic portfolio into high-value disease areas.

XTL trades on the Nasdaq Capital Market (NASDAQ: XTLB) and Tel Aviv Stock Exchange (TASE: XTLB.TA).

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; (vii) the Company’s ability to successfully consummate the acquisition of 85% of the outstanding shares of NeuroNOS Ltd. pursuant to the letter of intent signed by it and Beyond Air, Inc., and, if consummated, to successfully manage and integrate NeuroNos Ltd.; and (viii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: info@xtlbio.com
www.xtlbio.com